Official Title: "A Multicenter Study for the Discovery and Validation of ALS Biomarkers"
The purpose of this study is to collect biofluid samples for the banking and usage in ALS research. Through comparison of these samples, the researchers hope to learn more about the underlying cause of ALS, as well as find unique biological markers, which could be used to develop new therapies.
- Study Type: Observational
- Study Design: Observational Model: Case-Only, Time Perspective: Prospective
- Study Primary Completion Date: December 2012
Detailed Clinical Trial Description
The purpose of the research study is to collect blood samples and cerebrospinal fluid (CSF) from people with amyotrophic lateral sclerosis (ALS). These samples will be collected approximately every 4 months.
Criteria for Participation in this Clinical Trial
- Age 18 or older
- Diagnosis of suspected, possible, probable or definite ALS according to El Escorial Criteria
- Vital capacity (VC) at least 50 percent predicted
- Able to undergo multiple lumbar punctures
- Abnormal CSF pressure or intracranial/intraspinal tumors
- Use of anticoagulant medication that cannot be safely withheld
- Bleeding disorders
- This is a partial listing.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial: No
Clinical Trial Investigator Information
- Lead Sponsor
- Massachusetts General Hospital
- ALS Therapy Alliance
- Provider of Information About this Clinical Study
- Principal Investigator: Merit E. Cudkowicz, MD, Principal Investigator - Massachusetts General Hospital
- Overall Contact(s)
- Sarah Titus, MPH, 617-726-1398, email@example.com